Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and the Sanofi Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY) began the open-label, international Phase III ATLAS program of fitusiran (ALN-AT3, SAR439774) to treat hemophilia A and B. Top-line data are expected in 2H19.
The ATLAS-INH trial will evaluate fitusiran in about 50 patients with hemophilia A or B with inhibitors receiving prior on-demand therapy. The ATLAS-A/B trial will assess fitusiran in about 100 patients with hemophilia A or B without inhibitors receiving prior on-demand therapy. The ATLAS-PPX trial will evaluate fitusiran in about 100 patients with hemophilia A or B with or without inhibitors receiving prophylaxis therapy as prior standard of care (SOC). In ATLAS-PPX, patients will initially receive SOC for 6 months followed by fitusiran for 7 months...
BCIQ Target Profiles